Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

FGF Receptors: Cancer Biology and Therapeutics
Masaru Katoh, Hitoshi Nakagama
Medicinal Research Reviews (2013) Vol. 34, Iss. 2, pp. 280-300
Closed Access | Times Cited: 534

Showing 1-25 of 534 citing articles:

The Fibroblast Growth Factor signaling pathway
David M. Ornitz, Nobuyuki Itoh
Wiley Interdisciplinary Reviews Developmental Biology (2015) Vol. 4, Iss. 3, pp. 215-266
Open Access | Times Cited: 1797
Kinase-targeted cancer therapies: progress, challenges and future directions
Khushwant S. Bhullar, Naiara Orrego Lagarón, Eileen McGowan, et al.
Molecular Cancer (2018) Vol. 17, Iss. 1
Open Access | Times Cited: 1064
Targeting the tumour stroma to improve cancer therapy
Kenneth C. Valkenburg, Amber E. de Groot, Kenneth J. Pienta
Nature Reviews Clinical Oncology (2018) Vol. 15, Iss. 6, pp. 366-381
Open Access | Times Cited: 911
The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
Teresa Helsten, Sheryl K. Elkin, Elisa Arthur, et al.
Clinical Cancer Research (2015) Vol. 22, Iss. 1, pp. 259-267
Open Access | Times Cited: 688
Angiogenic signaling pathways and anti-angiogenic therapy for cancer
Zhenling Liu, Huanhuan Chen, Lili Zheng, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 543
Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review)
Masaru Katoh
International Journal of Oncology (2017) Vol. 51, Iss. 5, pp. 1357-1369
Open Access | Times Cited: 396
Upregulated lncRNA-UCA1 contributes to progression of hepatocellular carcinoma through inhibition of miR-216b and activation of FGFR1/ERK signaling pathway
Feng Wang, Hou‐Qun Ying, Bangshun He, et al.
Oncotarget (2015) Vol. 6, Iss. 10, pp. 7899-7917
Open Access | Times Cited: 344
FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)
Masaru Katoh
International Journal of Molecular Medicine (2016) Vol. 38, Iss. 1, pp. 3-15
Open Access | Times Cited: 343
Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1
Binyan Lin, Xiuming Song, Dawei Yang, et al.
Gene (2018) Vol. 654, pp. 77-86
Closed Access | Times Cited: 327
Fibroblast growth factor receptors as treatment targets in clinical oncology
Masaru Katoh
Nature Reviews Clinical Oncology (2018) Vol. 16, Iss. 2, pp. 105-122
Closed Access | Times Cited: 301
Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor
Timothy Perera, Eleonora Jovcheva, Laurence Mévellec, et al.
Molecular Cancer Therapeutics (2017) Vol. 16, Iss. 6, pp. 1010-1020
Open Access | Times Cited: 282
The role of tumor microenvironment in therapeutic resistance
Beomseok Son, Sungmin Lee, HyeSook Youn, et al.
Oncotarget (2016) Vol. 8, Iss. 3, pp. 3933-3945
Open Access | Times Cited: 245
Cancer stem cells in progression of colorectal cancer
Yujuan Zhou, Longzheng Xia, Heran Wang, et al.
Oncotarget (2017) Vol. 9, Iss. 70, pp. 33403-33415
Open Access | Times Cited: 234
Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer
Juan Miguel Cejalvo, Eduardo Martínez de Dueñas, Patricia Galván, et al.
Cancer Research (2017) Vol. 77, Iss. 9, pp. 2213-2221
Open Access | Times Cited: 220
Combined CSL and p53 downregulation promotes cancer-associated fibroblast activation
Maria-Giuseppina Procopio, Csaba László, Dania Al Labban, et al.
Nature Cell Biology (2015) Vol. 17, Iss. 9, pp. 1193-1204
Open Access | Times Cited: 207
Role of AKT and mTOR signaling pathways in the induction of epithelial-mesenchymal transition (EMT) process
Mostafa Karimi Roshan, Arash Soltani, Anvar Soleimani, et al.
Biochimie (2019) Vol. 165, pp. 229-234
Closed Access | Times Cited: 204
TGF-β-Induced Endothelial to Mesenchymal Transition in Disease and Tissue Engineering
Jin Ma, Gonzalo Sánchez‐Duffhues, Marie‐José Goumans, et al.
Frontiers in Cell and Developmental Biology (2020) Vol. 8
Open Access | Times Cited: 190
Therapeutics Targeting FGF Signaling Network in Human Diseases
Masaru Katoh
Trends in Pharmacological Sciences (2016) Vol. 37, Iss. 12, pp. 1081-1096
Closed Access | Times Cited: 187
Molecular genetics and targeted therapy of WNT-related human diseases (Review)
Masuko Katoh, Masaru Katoh
International Journal of Molecular Medicine (2017)
Open Access | Times Cited: 187
Runx2 is required for the proliferation of osteoblast progenitors and induces proliferation by regulating Fgfr2 and Fgfr3
Tetsuya Kawane, Xin Qin, Qing Jiang, et al.
Scientific Reports (2018) Vol. 8, Iss. 1
Open Access | Times Cited: 168
Interactome analysis reveals that lncRNA HULC promotes aerobic glycolysis through LDHA and PKM2
Chunqing Wang, Yongmei Li, Shuai Yan, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 161
Signaling pathways in cancer‐associated fibroblasts: recent advances and future perspectives
Zengli Fang, Qingcai Meng, Jin Xu, et al.
Cancer Communications (2022) Vol. 43, Iss. 1, pp. 3-41
Open Access | Times Cited: 134
New developments in the biology of fibroblast growth factors
David M. Ornitz, Nobuyuki Itoh
WIREs Mechanisms of Disease (2022) Vol. 14, Iss. 4
Open Access | Times Cited: 98
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
Masuko Katoh, Yohann Loriot, Giovanni Brandi, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 4, pp. 312-329
Closed Access | Times Cited: 63
Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment
Ruiwen Ruan, Li Li, Xuan Li, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 53
Page 1 - Next Page

Scroll to top